SCHEMBL30133151

SCHEMBL30133151

CCOC(=O)C1Cc2sc(NC(=O)[C@H](C)N)c(C(=O)c3c(F)cccc3F)c2C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.42
THRB P10828 2/20 0.39
KDM4E B2RXH2 3/20 0.38
HPGD P15428 3/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 4/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 7/20 0.37
NPSR1 Q6W5P4 3/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CXCR2 P25025 1/20 0.35
CXCR4 P61073 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30133140 0.95 PDE4B (0.40) PDE4BTHRBKDM4EHPGDALDH1A1
SCHEMBL30133088 0.87 MAPT (0.42) PDE4BTHRBKDM4EHPGDALDH1A1
SCHEMBL27238475 0.87 PDE4B (0.46) PDE4BKDM4EHPGDALDH1A1LMNA
SCHEMBL27238469 0.87 PDE4B (0.46) PDE4BKDM4EHPGDALDH1A1LMNA
SCHEMBL27238477 0.86 PDE4B (0.41) PDE4BTHRBKDM4EHPGDALDH1A1
SCHEMBL27238471 0.86 PDE4B (0.41) PDE4BTHRBKDM4EHPGDALDH1A1
SCHEMBL30133180 0.83 PDE4B (0.46) PDE4BKDM4EHPGDALDH1A1POLB
SCHEMBL30133147 0.83 PDE4B (0.46) PDE4BKDM4EHPGDALDH1A1POLB
SCHEMBL30133169 0.82 RAB9A (0.41) PDE4BTHRBKDM4EHPGDALDH1A1
SCHEMBL30133123 0.81 ALDH1A1 (0.42) KDM4EHPGDALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2024-06-13 US disclosed
EP-4380940-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2024-06-12 EP disclosed
WO-2023012130-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS GABRA1, GABRA5, GABRB1 PDE4B 231/4885THRB 589/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.